AstraZeneca India Pharma on Thursday said it has received approval from the government authority for the import, sale, and distribution of a medication used in treating non-small cell lung cancer.
The company has received approval for Osimertinib tablets in strength of 40mg and 80mg. The approval marks a critical step for monotherapy in the treatment of patients with locally advanced, unresectable (Stage III) lung cancer.
×
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access.
Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Combo
Yearly
Monthly
Already a Member? Sign In Now
Advertisement
Advertisement
Advertisement